Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Supplemental material
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Open Access | 10.1172/JCI213755

Corrigendum to Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation

Xinchun Zhang, Jinjiang Xue, Cunyan Zhao, Chenqiuyue Zeng, Jiacheng Zhong, Gangfeng Yu, Xi Yang, Yao Ling, Dazhen Li, Jiaxiao Yang, Yun Xiu, Hongda Li, Shiyuan Hong, Liangjun Qiao, Song Chen, Q. Richard Lu, Yaqi Deng, Zhaohua Tang, and Fanghui Lu

Find articles by Zhang, X. in: PubMed | Google Scholar

Find articles by Xue, J. in: PubMed | Google Scholar

Find articles by Zhao, C. in: PubMed | Google Scholar

Find articles by Zeng, C. in: PubMed | Google Scholar

Find articles by Zhong, J. in: PubMed | Google Scholar

Find articles by Yu, G. in: PubMed | Google Scholar

Find articles by Yang, X. in: PubMed | Google Scholar

Find articles by Ling, Y. in: PubMed | Google Scholar

Find articles by Li, D. in: PubMed | Google Scholar

Find articles by Yang, J. in: PubMed | Google Scholar

Find articles by Xiu, Y. in: PubMed | Google Scholar

Find articles by Li, H. in: PubMed | Google Scholar

Find articles by Hong, S. in: PubMed | Google Scholar

Find articles by Qiao, L. in: PubMed | Google Scholar

Find articles by Chen, S. in: PubMed | Google Scholar

Find articles by Lu, Q. in: PubMed | Google Scholar

Find articles by Deng, Y. in: PubMed | Google Scholar

Find articles by Tang, Z. in: PubMed | Google Scholar

Find articles by Lu, F. in: PubMed | Google Scholar

Published November 16, 2026 - More info

Published in Volume 136, Issue 22 on November 16, 2026
J Clin Invest. 2026;136(22):e213755. https://doi.org/10.1172/JCI213755.
© 2026 Zhang et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 16, 2026 - Version history
View PDF

Related article:

Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation
Xinchun Zhang, Jinjiang Xue, Cunyan Zhao, Chenqiuyue Zeng, Jiacheng Zhong, Gangfeng Yu, Xi Yang, Yao Ling, Dazhen Li, Jiaxiao Yang, Yun Xiu, Hongda Li, Shiyuan Hong, Liangjun Qiao, Song Chen, Q. Richard Lu, Yaqi Deng, Zhaohua Tang, Fanghui Lu
Xinchun Zhang, Jinjiang Xue, Cunyan Zhao, Chenqiuyue Zeng, Jiacheng Zhong, Gangfeng Yu, Xi Yang, Yao Ling, Dazhen Li, Jiaxiao Yang, Yun Xiu, Hongda Li, Shiyuan Hong, Liangjun Qiao, Song Chen, Q. Richard Lu, Yaqi Deng, Zhaohua Tang, Fanghui Lu
OLIG2, a master transcription factor in glioblastoma stem cells, enables immune evasion by suppressing CXCL10. Targeting OLIG2 overcomes immunotherapy resistance and improves survival.
Research Article Cell biology Immunology Oncology

Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation

  • Text
  • PDF
Abstract

Glioblastomas (GBMs) are highly lethal brain tumors with limited treatment options and resistance to immune checkpoint inhibitors due to their immunosuppressive tumor microenvironment. Here, we identify OLIG2 as a key regulator of immune evasion in GBM stem-like cells, which inhibits CD8+ T cell–dependent antitumor immunity while promoting protumor macrophage polarization. Mechanistically, OLIG2 recruited HDAC7 to repress CXCL10 transcription, inducing STAT3 activation in tumor-associated macrophages (TAMs) and decreasing CD8+ T cell infiltration and activation. Genetic deletion of OLIG2 significantly increased CXCL10 secretion, shifting TAMs toward an antitumor phenotype and enhancing CD8+ T cell activities. Furthermore, upregulated OLIG2 expression was correlated with resistance to immune checkpoint inhibitors in patients with GBMs. OLIG2 inhibition by either genetic deficiency or pharmacological targeting with CT-179 sensitized GBM tumors to anti–PD-L1 therapy, enhancing antitumor immune responses and prolonging survival. Our findings reveal OLIG2+ glioma stem-like cells as critical mediators of immune evasion and identify the OLIG2/HDAC7/CXCL10 axis as a potential therapeutic target to enhance immune checkpoint inhibitor efficacy and improve immunotherapy outcomes in aggressive GBMs.

Authors

Xinchun Zhang, Jinjiang Xue, Cunyan Zhao, Chenqiuyue Zeng, Jiacheng Zhong, Gangfeng Yu, Xi Yang, Yao Ling, Dazhen Li, Jiaxiao Yang, Yun Xiu, Hongda Li, Shiyuan Hong, Liangjun Qiao, Song Chen, Q. Richard Lu, Yaqi Deng, Zhaohua Tang, Fanghui Lu

×

Original citation: J Clin Invest. 2026;136(5):e195556. https://doi.org/10.1172/JCI195556

Citation for this corrigendum: J Clin Invest. 2026;136(22):e213755. https://doi.org/10.1172/JCI213755

Following publication of this article, the journal was notified that Figure 4A was a representative subset of the available data. The correct figure 4A, including the complete dataset, appears below and in the updated HTML and PDF versions of the article. In addition, a duplicated data point was identified in supplemental figure 2H. The supplemental data file has been updated with the correct figure, and the supporting data values file has been updated online with correction information for 4A and supplemental figure 2H.

CXCL10 reduces M2-like polarization of macrophages by inhibiting STAT3 signFigure 4

CXCL10 reduces M2-like polarization of macrophages by inhibiting STAT3 signaling. (A) qPCR of mRNA expression of antiinflammatory markers in BMDMs treated with CM from the indicated groups (n = 4).

The authors regret the errors.

Supplemental material

View Supplemental data

View Supporting data values

Footnotes

See the related article at Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation.

Version history
  • Version 1 (November 16, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Supplemental material
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts